IP Library Granted Patent US 8,895,752
Granted Patent B2
US 8,895,752 · App. 13/353,686 · Granted Nov 25, 2014

Alkylsulfonyl-substituted thiazolide compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,752
App. No.
13/353,686
Granted
Nov 25, 2014
Kind
B2
Abstract

A new class of alkylsulfonyl-substituted thiazolide compounds is described. These compounds show strong activity against hepatitis virus.

Claims (22)

1. A compound having a formula (I)

wherein one of R 6 or R 9 is C 1 -C 6 alkylsulfonyl, and the other is hydrogen,

or a pharmaceutically acceptable salt or ester thereof.

2. A compound according to claim 1 , selected from the group consisting of structures:

3. A compound according to claim 1 , selected from the group consisting of:

4. The compound of claim 1 , wherein R 6 or R 9 is SO 2 CH 3 and the other R 6 or R 9 is H.

5. The compound of claim 1 , wherein the compound of formula (I) is the pharmaceutically acceptable ester.

6. The compound of claim 5 , wherein the pharmaceutically acceptable ester is a (C 1 -C 6 )-acyloxy.

7. The compound of claim 1 , wherein the compound is the pharmaceutically acceptable salt.

8. The compound of claim 7 , wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycero-phosphate, hemisulfate, heptanoate, hexanoate, hydrochloride hydrobromide, hydroiodide, 2-hydroxyethane-sulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, thiocyanate, tosylate and undecanoate.

9. The compound of claim 4 , wherein the compound of formula (I) is the pharmaceutically acceptable ester.

10. The compound of claim 9 , wherein the pharmaceutically acceptable ester is a (C 1 -C 6 )-acyloxy.

11. A pharmaceutical composition comprising a compound of claim 1 and a carrier.

12. A pharmaceutical composition comprising a compound of claim 2 and a carrier.

13. A pharmaceutical composition comprising a compound of claim 3 and a carrier.

14. A pharmaceutical composition comprising a compound of claim 4 and a carrier.

15. A pharmaceutical composition comprising a compound of claim 5 and a carrier.

16. A pharmaceutical composition comprising a compound of claim 6 and a carrier.

17. A pharmaceutical composition comprising a compound of claim 7 and a carrier.

18. A pharmaceutical composition comprising a compound of claim 8 and a carrier.

19. A pharmaceutical composition comprising a compound of claim 9 and a carrier.

20. A pharmaceutical composition comprising a compound of claim 10 and a carrier.

Assignments (5)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →
SECURITY INTEREST Recorded Jul 2, 2018
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 046254/0524 →
SECURITY INTEREST Recorded Dec 22, 2017
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 044472/0001 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2015
From: U.S. BANK NATIONAL ASSOCIATION
To: ROMARK LABORATORIES, L.C.; ROMARK MANUFACTURING, LLC; LAPICOR, N.V.
Reel/Frame 035108/0474 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: ROMARK LABORATORIES, L.C.; ROMARK MANUFACTURING, LLC; LAPICOR, N.V.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 031156/0923 →